Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc (NDRA) pioneers advanced medical imaging through its TAEUS technology and Nexus 128 system, offering non-invasive solutions for liver diagnostics and preclinical research. This page consolidates all official announcements and third-party analyses about the company’s technological advancements and strategic initiatives.
Access real-time updates on regulatory milestones, clinical trial progress, and partnerships driving innovation in photoacoustic imaging. Investors and researchers will find detailed coverage of product developments like the TAEUS liver fat quantification system and Nexus 128’s 4D scanning capabilities.
Key updates include financial results, intellectual property filings, and collaborations with global research institutions. All content is verified for accuracy and relevance to ensure informed decision-making about this emerging leader in cost-effective diagnostic imaging.
Bookmark this page to stay informed about NDRA’s progress in addressing unmet needs in NAFLD/NASH diagnosis and expanding applications of thermo-acoustic ultrasound technology across healthcare markets.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announces its participation in two significant virtual medical conferences: The Liver Meeting Digital Experience (TLMdX) from Nov. 13-16, 2020, and the Radiological Society of North America (RSNA) annual meeting from Nov. 29-Dec. 5. This exhibition aims to boost the commercialization of its Thermo Acoustic Enhanced UltraSound (TAEUS®) System, which provides a non-invasive method for assessing liver fat. The company has also submitted a 510(k) application to the FDA for TAEUS® clearance, with CE Mark approval already in place.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will release its third quarter financial results on November 16, 2020, after U.S. market close. A conference call will follow at 4:30 p.m. ET to discuss results and company updates. ENDRA is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at revolutionizing tissue visualization at a fraction of the cost of traditional imaging methods. TAEUS focuses on assessing liver conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) and aims to expand into other clinical applications.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has been granted European Patent EP 3 294 142 B1, expanding its TAEUS technology applications beyond Non-Alcoholic Fatty Liver Disease (NAFLD). This patent increases ENDRA's total to 75 worldwide, enhancing its commercial prospects with innovative imaging techniques. CEO Francois Michelon noted the importance of this patent as the company ramps up sales efforts in Europe, where they established their first clinical evaluation reference site. The patent potentially opens up a market exceeding $21 billion in liver disease diagnostics.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has received international patent registrations DM/210628 and DM/210629 for its Fatty Liver Imaging Probe (FLIP) from the World Intellectual Property Organization (WIPO). This protection reinforces ENDRA's intellectual property for its TAEUS technology, aimed at addressing the unmet diagnostic needs for Non-Alcoholic Fatty Liver Disease (NAFLD), affecting over a billion people globally. With a growing portfolio of 73 patents, ENDRA is positioning itself for commercialization in Europe and beyond.
ENDRA Life Sciences (NASDAQ:NDRA) announced its participation in the 4th Annual H.C. Wainwright NASH Investor Conference on October 5, 2020, at 2:00 p.m. Eastern time. The conference presentation will be accessible via a live webcast through the conference's website or the company's Investor Relations page. ENDRA's innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology aims to revolutionize tissue visualization, targeting chronic liver diseases affecting over a billion people globally.
More details can be found on the company's website.
ENDRA Life Sciences (NASDAQ:NDRA) announced its participation in Lake Street's Fourth Annual Best Ideas Growth (BIG4) Conference on September 17, 2020. The event will take place virtually, featuring one-on-one and group meetings with investors. ENDRA aims to showcase its innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers cost-effective imaging solutions. This conference will include approximately 85 public growth companies, providing a platform for institutional investors to engage directly with executives.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced its participation in the H.C. Wainwright 22nd Annual Virtual Global Investment Conference on September 16, 2020, at 11 a.m. ET. Management will present the company's innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which visualizes tissue at a fraction of the cost of traditional imaging methods. The conference runs from September 14-16, and one-on-one investor meetings can be arranged. The presentation will be available for livestreaming and replay via the company's website.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) announced its participation in the LD 500 Virtual Investor Conference from September 1-4, 2020. The company will present on September 3, 2020, at 2:00 PM ET. CEO Francois Michelon will lead the presentation, which includes one-on-one meetings. ENDRA focuses on Thermo Acoustic Enhanced Ultrasound (TAEUS), an innovative technology for assessing liver conditions like NAFLD and NASH, aiming to provide cost-effective diagnostics. For details, visit their webcast.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) is showcasing its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology at the Digital International Liver Congress (ILC) from August 27-29, 2020. This virtual event allows ENDRA to enhance brand awareness and commercial strategies by exhibiting its TAEUS Fatty Liver Imaging Probe (FLIP) System. Following the CE Mark obtained earlier this year, ENDRA focuses on establishing clinical evaluation sites in Europe and has submitted a 510(k) application to the U.S. FDA for TAEUS FLIP, which is currently under review.
ENDRA Life Sciences (NASDAQ: NDRA) announced the early exercise of about 7.1 million common stock warrants, generating approximately $5 million in gross proceeds. Since July 1, 2020, this early exercise by significant shareholders is viewed as a vote of confidence in ENDRA's developments, including CE Mark approval in Europe and the submission for FDA clearance of its TAEUS FLIP system. The funds are expected to extend the company's cash runway for establishing evaluation sites and initiating sales in Europe, with hopes for U.S. commercialization this year.
